Michael Calderon

Michael Calderon

Auto-generated profile, based on publicly available information

Michael Calderon

Department of Cell Biology, University of Pittsburgh, Pittsburgh, PA 15261, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2018 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
AMAshley V. Menk
Ashley V. Menk
NSNicole Scharping
Nicole Scharping
DRDayana B. Rivadeneira
Dayana B. Rivadeneira
MCMichael J. Calderon
Michael J. Calderon
MWMcLane J. Watson
McLane J. Watson
GDGreg M. Delgoffe
Greg M. Delgoffe
Despite remarkable responses to cancer immunotherapy in a subset of patients, many patients remain resistant to these therapies. The tumor microenvironment can impose metabolic restrictions on T cell function, creating a resistance mechanism to immunotherapy. We have previously shown tumor-infiltrating T cells succumb to progressive loss of metabolic sufficiency, characterized by repression of mitochondrial activity that cannot be rescued by PD-1 blockade. 4-1BB, a costimulatory molecule highly expressed on exhausted T cells, has been shown to influence metabolic function. We hypothesized that 4-1BB signaling might provide metabolic support to tumor-infiltrating T cells. 4-1BB costimulation of CD8+ T cells results in enhanced mitochondrial capacity (suggestive of fusion) and engages PGC1α-mediated pathways via activation of p38-MAPK. 4-1BB treatment of mice improves metabolic sufficiency in endogenous and adoptive therapeutic CD8+ T cells. 4-1BB stimulation combined with PD-1 blockade results in robust antitumor immunity. Sequenced studies revealed the metabolic support afforded by 4-1BB agonism need not be continuous and that a short course of anti–4-1BB pretreatment was sufficient to provide a synergistic response. Our studies highlight metabolic reprogramming as the dominant effect of 4-1BB therapy and suggest that combinatorial strategies using 4-1BB agonism may help overcome the immunosuppressive metabolic landscape of the tumor microenvironment. Graphical Abstract

17 March 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
FZFurong Zeng
Furong Zeng
ZCZhizhao Chen
Zhizhao Chen
RCRao Chen
Rao Chen
WSWilliam J. Shufesky
William J. Shufesky
MBMohna Bandyopadhyay
Mohna Bandyopadhyay
AMAdrian E. Morelli
Adrian E. Morelli
B cell sensitization to allografts is promoted by graft-derived extracellular vesicles concentrated by specialized macrophages in lymphoid tissues.

30 November 2020 in PLOS Biology
Verified
Journal Article
Open access
PDF file
RHRyan Houston
Ryan Houston
SSShiori Sekine
Shiori Sekine
MCMichael J. Calderon
Michael J. Calderon
FSFayaz Seifuddin
Fayaz Seifuddin
GWGuanghui Wang
Guanghui Wang
YSYUSUKE SEKINE
YUSUKE SEKINE
The metabolite acetyl-coenzyme A (acetyl-CoA) serves as an essential element for a wide range of cellular functions including adenosine triphosphate (ATP) production, lipid synthesis, and protein acetylation. Intracellular acetyl-CoA concentrations are associated with nutrient availability, but the mechanisms by which a cell responds to fluctuations in acetyl-CoA levels remain elusive. Here, we generate a cell system to selectively manipulate the nucleo-cytoplasmic levels of acetyl-CoA using clustered regularly interspaced short palindromic repeat (CRISPR)-mediated gene editing and acetate supplementation of the culture media. Using this system and quantitative omics analyses, we demonstrate that acetyl-CoA depletion alters the integrity of the nucleolus, impairing ribosomal RNA synthesis and evoking the ribosomal protein-dependent activation of p53. This nucleolar remodeling appears to be mediated through the class IIa histone deacetylases (HDACs). Our findings highlight acetylation-mediated control of the nucleolus as an important hub linking acetyl-CoA fluctuations to cellular stress responses.

11 October 2022 in Cancer Research
Verified
Journal Article
Open access
PDF file
HAHuda I. Atiya
Huda I. Atiya
LFLeonard Frisbie
Leonard Frisbie
EGEster Goldfeld
Ester Goldfeld
TOTaylor Orellana
Taylor Orellana
NDNicole Donnellan
Nicole Donnellan
LCLan Rinda Coffman
Lan Rinda Coffman
Ovarian clear cell carcinoma (OCCC) is a deadly and treatment-resistant cancer, which arises within the unique microenvironment of endometriosis. In this study, we identified a subset of endometriosis-derived mesenchymal stem cells (enMSC) characterized by loss of CD10 expression that specifically support OCCC growth. RNA sequencing identified alterations in iron export in CD10-negative enMSCs and reciprocal changes in metal transport in cocultured OCCC cells. CD10-negative enMSCs exhibited elevated expression of iron export proteins hephaestin and ferroportin and donate iron to associated OCCCs, functionally increasing the levels of labile intracellular iron. Iron is necessary for OCCC growth, and CD10-negative enMSCs prevented the growth inhibitory effects of iron chelation. In addition, enMSC-mediated increases in OCCC iron resulted in a unique sensitivity to ferroptosis. In vitro and in vivo, treatment with the ferroptosis inducer erastin resulted in significant death of cancer cells grown with CD10-negative enMSCs. Collectively, this work describes a novel mechanism of stromal-mediated tumor support via iron donation. This work also defines an important role of endometriosis-associated MSCs in supporting OCCC growth and identifies a critical therapeutic vulnerability of OCCC to ferroptosis based on stromal phenotype. Significance: Endometriosis-derived mesenchymal stem cells support ovarian clear cell carcinoma via iron donation necessary for cancer growth, which also confers sensitivity to ferroptosis-inducing therapy.

12 November 2021 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
AMAmitava Mukherjee
Amitava Mukherjee
MEMichael W. Epperly
Michael W. Epperly
DSDonna Shields
Donna Shields
WHWen Hou
Wen Hou
RFRenee Fisher
Renee Fisher
JGJoel Greenberger
Joel Greenberger
The role of cellular senescence in radiation-induced pulmonary fibrosis (RIPF) and the underlying mechanisms are unknown. We isolated radiation-induced senescent tdTOMp16 positive mesenchymal stem cells, established their absence of cell division, then measured levels of irradiation-induced expression of biomarkers of senescence by RNA-seq analysis. We identified a Log2 6.17-fold upregulation of tyrosine kinase Fgr, which was a potent inducer of biomarkers of fibrosis in target cells in non-contact co-cultures. Inhibition of Fgr by shRNA knockdown did not block radiation-induced senescence in vitro; however, both shRNA knockdown, or addition of a specific small-molecule inhibitor of Fgr, TL02-59, abrogated senescent cell induction of profibrotic genes in transwell-separated target cells. Single-cell RNA-seq (scRNAseq) analysis of mouse lungs at day 150 after 20 Gy thoracic irradiation revealed upregulation of Fgr in senescent neutrophils, and macrophages before detection of lung fibrosis. Thus, upregulated Fgr in radiation-induced senescent cells mediates RIPF and is a potential therapeutic target for the prevention of this radiation late effect.

19 May 2022 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
ASAshwin Somasundaram
Ashwin Somasundaram
ACAnthony R. Cillo
Anthony R. Cillo
CLCaleb Lampenfeld
Caleb Lampenfeld
CWCreg J. Workman
Creg J. Workman
SKSheryl Kunning
Sheryl Kunning
DVDario A.A. Vignali
Dario A.A. Vignali
Many cancer patients do not develop a durable response to the current standard-of-care immunotherapies, despite substantial advances in targeting immune inhibitory receptors. A potential compounding issue, which may serve as an unappreciated, dominant resistance mechanism, is an inherent systemic immune dysfunction that is often associated with advanced cancer. Minimal response to inhibitory receptor (IR) blockade therapy and increased disease burden have been associated with peripheral CD8+ T-cell dysfunction, characterized by suboptimal T-cell proliferation and chronic expression of IRs (e.g., PD1 and LAG3). Here, we demonstrated that approximately a third of cancer patients analyzed in this study have peripheral CD8+ T cells that expressed robust intracellular LAG3 (LAG3IC), but not surface LAG3 (LAG3SUR) due to a disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) cleavage. This is associated with poor disease prognosis and decreased CD8+ T-cell function, which could be partially reversed by anti-LAG3. Systemic immune dysfunction was restricted to CD8+ T cells, including, in some cases, a high percentage of peripheral naïve CD8+ T cells, and was driven by the cytokine IL6 via STAT3. These data suggest that additional studies are warranted to determine if the combination of increased LAG3IC in peripheral CD8+ T cells and elevated systemic IL6 can serve as predictive biomarkers and identify which cancer patients may benefit from LAG3 blockade.